Abbott Laboratories Limited

Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4XE, UK
Telephone: +44 (0)1628 773 355
Fax: +44 (0)1628 644 185
WWW: http://www.abbottuk.com
Medical Information e-mail: ukmedinfo@abbott.com
Out of Hours Telephone: +44 (0)1628 774 920
Summary of Product Characteristics last updated on the eMC: 26/08/2009
SPC Chirocaine 2.5mg/ml solution for injection/concentrate for solution for infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 26/08/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6. 3 - Shelf Life
  • Change to section 6. 4 - Special Precautions for Storage
Date of revision of text on the SPC:   01-Aug-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company


  • In Section 2 (Qualitative and Quantitative Composition), the statement 'Full a full list of excipients, see section 6.1' has been placed after 'Excipients: 3.6mg/ml of sodium per bag'.
  • In Section 3 (Pharmaceutical form), the statement 'practically free from particles' has been removed.
  • In Section 4.4 (Special warnings and precautions for use), A warning regarding patients on a sodium controlled diet has been added.
  • Section 4.8 (Undesirable effects), has been completely reformatted to MedDRA terminology and frequency.
  • In Section 6.3 (Shelf life), the paragraphs have been clarified to show the difference between using the product immediately and dilutions in 0.9% sodium chloride solution.
  • In Section 6.4 (Special precautions for storage), a statement regarding the storage of reconstituted product has been added.
  • Updated on 16/05/2007 and displayed until 26/08/2009
    Reasons for adding or updating:
    • Change to section 4.8 - Undesirable Effects
    Date of revision of text on the SPC:   04/2007
    Legal Category:   POM
    Black Triangle (CHM):   NO

    Free-text change information supplied by the pharmaceutical company

    Change to section 4.8 - Undesirable effects 
    Updated on 06/12/2006 and displayed until 16/05/2007
    Reasons for adding or updating:
    • Removal of Black Triangle
    Date of revision of text on the SPC:   12/2006
    Legal Category:   POM
    Black Triangle (CHM):   NO

    Free-text change information supplied by the pharmaceutical company

    Removal of black triangle.
    Updated on 13/06/2005 and displayed until 06/12/2006
    Reasons for adding or updating:
    • Change to section 3 - pharmaceutical form
    • Change to section 4.1 - Therapeutic Indications
    • Change to section 4.2 - Posology and Method of Administration
    • Change to section 4.4 - Special Warnings and Precautions for Use
    • Change to section 4.6 - Pregnancy and Lactation
    • Change to section 4.7 - Effects on Ability to Drive and Use Machines
    • Change to section 5 - Pharmacological Properties
    • Change to section 6.2 - Incompatibilities
    • Change to section 6. 4 - Special Precautions for Storage
    • Change to section 6. 5 - Nature and Contents of Container
    • Change to section 6. 6 - Instruction for Use/Handling
    • Change to section 10 (date of (partial) revision of the text
    Updated on 24/09/2002 and displayed until 13/06/2005
    Reasons for adding or updating:
    • Change to section 6. 3 - Shelf Life
    Updated on 30/11/2001 and displayed until 24/09/2002
    Reasons for adding or updating:
    • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

    Active Ingredients/Generics

     
       levobupivacaine hydrochloride


    © 2010 Datapharm Communications Ltd

    Go to www.medicines.org.uk